Statin Class in Session

Program Goals

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Dyslipidemia and Risk for Diabetes

How Statins Could Impair Glucose and Insulin Metabolism

Risk for New-Onset Diabetes With Statins Increases With Age

Additive Effect of Fasting Glucose and Statin Intensity on Risk for New-Onset Diabetes

Risk for Diabetes Based on Risk Factors and Statin Dose

Genetics of HMGCR AND PCSK9 Suggest New-Onset Diabetes is On-Target Effect

Risk for New-Onset Diabetes: Meta-Analysis of Placebo-Controlled Statin Trials

Changes in LDL-C and Glycemia in Head-to-Head Statin Trials

INTREPID Study: Impact of Pitavastatin and Pravastatin on Mean Fasting Glucose and HbA1c

Pitavastatin Has a Neutral Effect on FBG in Non-Diabetic Subjects Across the Dose Range

Pitavastatin Does Not Increase New-Onset Diabetes

Ezetimibe Lowers LDL-C Without Increasing Risk for New-Onset Diabetes

NLA Recommendations for Managing Dyslipidemia

Guideline Updates on the Use of PCSK9 Inhibitors

2017 AACE Lipid Guidelines

Interprofessional Team Approach: Increase Efforts to Prevent Diabetes

Take-Home Messages

Abbreviations

Abbreviations (cont)